Skip To Main Content
Catalent Cell on Muck Rack

Catalent Cell

As seen in: Cell & Gene Therapy Insights, Pharma's Almanac
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Catalent Cell’s profile

Articles by Catalent Cell

Accelerating your gene therapy to patients: not all platforms are created equal

|
By George Buchman, Catalent Cell, Thomas VanCott
| Cell & Gene Therapy Insights Verified
Thursday June 22nd 2023 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. The field of gene therapy manufacturing faces a significant hurdle in the form of a lack of process standardization. There are ways to address this challenge, however, such as using standardized methods, materials, analytics, and documentation.
Open in Who Shared Issue with article?

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

|
By Nice Insight, Catalent Cell
| Pharma's Almanac Verified
The ex vivo cell and gene therapy medicine field has entered into a new era driven by the registration of the first autologous products, namely Kymriah (Novartis, 2017, U.S.), Yescarta (Kite/Gilead, 2017, U.S.), and Strimvelis (GSK/Orchard, 2016, Europe). Despite this very promising context, cell-based processes are far from being mature from an industrial perspective. One proof is the frequent news of quality issues (out-of-specification) on cell therapy products.
Open in Who Shared Issue with article?
Show More